SOURCE: Cell Bio-Systems

March 28, 2006 08:28 ET

Tulip BioMed Adds Expert Resources to Its Board of Advisors and Board of Scientific Advisors

Renowned Specialists in Their Fields Join Advisory Teams to Support Living Tissue Management Biotech Company

SAN DIEGO, CA -- (MARKET WIRE) -- March 28, 2006 -- Tulip BioMed, Inc., formerly known as Cell Bio-Systems, Inc. (OTC: CBSI), a developer of medical devices and patented technologies for the living tissue markets, including plastic, cosmetic, and orthopedic surgeries, today announced it has added a significant group of medical industry and business experts to two corporate advisory boards: a Board of Scientific Advisors (BOSA) and a Board of Advisors (BOA).

The Board of Scientific Advisors is comprised of internationally renowned medical doctors, inventors, authors and professors in the cosmetic and plastic surgical fields. These healthcare professionals have agreed to assist Tulip BioMed in assessing its technology advancements, evaluating its products, and identifying the trends or issues in the industry that will impact living tissue procedures. The advisors on this group will work with BOSA Chairman Robert E. Peters, Ph.D., M.D., F.A.A.F.P. They include:

--  Robert W. Alexander, M.D., D.M.D., F.I.C.S.
--  Robert A. Ersek, M.D., F.A.C.S.
--  John Johnson, CEO, Tulip Medical
--  J. William Little, M.D., F.A.C.S.
--  Thomas F. Mitts, M.D.
--  Edward Racek, M.D.
--  Oscar M. Ramirez, M.D., F.A.C.S
--  Luiz S. Toledo, M.D.
--  Woffles T.L. Wu, M.B., B.S., F.R.C.S., F.A.M.S.
"The solutions being developed by Tulip BioMed will advance the industry by helping to make fat grafting an easier and more consistent process for cosmetic plastic surgery," said Dr. Robert Alexander. "Because fat is an autologous (patient's own) tissue, it is safe, preferable for use as a volume filler, and likely to be more long-lasting. We're pleased to help the company assess instrumentation and procedures that will make live tissue management even more successful and safer for our patients."

The Board of Advisors will be headed by Tulip BioMed President and COO Darin Andersen. The BOA team is composed of business professionals, entrepreneurs, marketing, accounting and legal specialists who will advise the company on infrastructure development, operational issues, sales and marketing promotion, as well as create opportunities for funding and networking contacts. This board includes:

--  Ratan Bajaj, vice president, Global Operations
--  Dr. Joel Berger, founder of Cytori Therapeutics
--  John Johnson, CEO, Tulip Medical
--  Jay Poe, president, Nypro N.A.
--  Beth Walsh, principal, Clearpoint Agency
--  J. Harlow Wright, Esq., general counsel
--  Ken Yonika, financial consultant
--  William Paulin, Ph.D., business consultant
Full biographies of the team members, as well as that of company management, can be found at

"We are honored that these knowledgeable and accomplished people have agreed to join our advisory boards and help us refine and position our products for the living tissue markets," said Marc Pilkington, founder and CEO of Tulip BioMed. "I look forward to working with the teams to bring our new disposable products to market across a wide range of applications that will benefit both physicians and patients worldwide."

About Tulip BioMed

Tulip BioMed, Inc., formerly known as Cell Bio-Systems, Inc., (OTC: CBSI) is a Nevada corporation with operations based in San Diego, California. Founded in 2004, Tulip BioMed is a medical device, biotechnology company that manufactures and distributes patented technologies for the plastic and cosmetic surgery, biopsy, orthopedic surgery, stem cell therapy and other living tissue markets. Tulip BioMed is the exclusive licensee of patented syringe connection devices that use the worldwide-recognized Tulip brand name. Tulip BioMed manufactures, markets, and distributes medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets. On the Web: Products are available for sale at

Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed, formerly Cell Bio-Systems, Inc. ("Cell Bio-Systems"), which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information

  • Contact:
    Beth Walsh
    Clearpoint Agency, Inc.
    Email Contact